- Document Number:
20150366501
- Appl. No:
14/763875
- Application Filed:
January 28, 2014
- نبذة مختصرة :
The present invention relates to the field of biomarkers and in particular to their utilisation in treatment. Embodiments of the invention have been particularly developed as biomarkers enabling optimisation of treatment regimes and as uses of the biomarkers in tests for the prediction of optimised treatments and treatment outcomes in the treatment of Major Depressive Disorder (MDD).
- Assignees:
BRC Operations Pty Limited (Ultimo, AU)
- Claim:
1. A method of determining a medical treatment outcome in a brain-related condition of a subject, the method including the steps of: a) determining the state of the white matter circuits of the subject's brain; and b) utilising said state of the white matter circuits to predict the likely medical treatment outcome.
- Claim:
2. The method as claimed in claim 1 wherein step a) includes conducting diffusion tensor imaging (DTI) of the subject's brain.
- Claim:
3. The method as claimed in claim 1 wherein step b) includes determining the state of anterior cingulate or the limbic circuits as a biomarker of the likely medical treatment outcome.
- Claim:
4. The method as claimed in claim 2 wherein the brain-related condition is Major Depressive Disorder (MDD).
- Claim:
5. The method as claimed in claim 4 wherein the treatment is a treatment for depression.
- Claim:
6. The method as claimed in claim 5 wherein the treatment for depression comprises the administration of an antidepressant medication (ADM).
- Claim:
7. The method as claimed in claim 6 wherein the ADM comprises venlafaxine-XR.
- Claim:
8. The method as claimed in claim 5 wherein treatment for depression comprises the administration of an ADM selected from escitalopram, sertraline and venlafaxine-extended release (venlafaxine-XR).
- Claim:
9. The method as claimed in claim 1 wherein the degree of connectivity of the cingulate portion of the cingulum and the stria terminalis are determined in step a).
- Claim:
10. A method of predicting symptom remission or symptom response in a patient with Major Depressive Disorder (MDD) when treated with a selected ADM comprising the steps of: a) performing diffusion tensor imaging (DTI) of the cingulate gyrus and the stria terminalis to measure fractional anisotropy (FA) of the white matter circuits in these areas of the patient's brain; and b) utilising said measure of step a) to predict symptom remission or symptom response, wherein a ratio of FA values for the cingulate portion of the cingulum to FA values for the stria terminals below 1 is predictive of symptom remission.
- Claim:
11. A method of predicting non-remission in a patient with Major Depressive Disorder (MDD) when treated with a selected ADM comprising the steps of: a) performing Diffusion Tensor Imaging (DTI) of the cingulate gyrus and the stria terminalis to obtain a measure of fractional anisotropy (FA) in these areas of the patient's brain; and b) utilising said measure of step a) to predict non-remission, wherein a ratio of FA values for the stria terminalis to FA values for the cingulate portion of the cingulum below 1 is predictive of non-remission.
- Claim:
12. A method of treating Major Depressive Disorder (MDD) in a patient, wherein said MDD is associated with a particular state of the white matter circuits of the patient's brain, said method comprising the steps of: a) performing diffusion tensor imaging (DTI) to obtain a measure of fractional anisotropy (FA) in an area of the patient's brain; b) comparing said measure of step a) with a reference set of FA measures obtained from MDD patients to establish a correlation between said measure of with a corresponding FA measure of the reference set; c) selecting an antidepressant medication (ADM) based on said correlation of step b), and wherein said corresponding FA measure of the reference set has been linked to beneficial treatment outcome in MDD patients having been treated with said ADM; and d) administering said ADM selected in step c) to said patient to treat said MDD.
- Claim:
13. The method as claimed in claim 12 wherein DTI of the cingulate gyrus and the stria terminalis is performed in step a).
- Claim:
14. The method as claimed in claim 13 wherein the ADM is selected from the group consisting of selective serotonin reuptake inhibitors (SSRIs) and serotonin reuptake inhibitors (SNRIs).
- Claim:
15. The method as claimed in claim 14 wherein the ADM is selected from escitalopram, sertraline and venlafaxine-extended release (venlafaxine-XR).
- Current International Class:
61; 01; 61; 61; 61; 61
- الرقم المعرف:
edspap.20150366501
Processing Request
No Comments.